Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | NOS3 | P29474 | 3/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | NOS2 | P35228 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30825597 | 0.91 | KLK5 (0.45) | KLK5PPARGPPARATACR1CTSS | |
| SCHEMBL27207121 | 0.90 | PPARA (0.53) | PPARGPPARACTSSCTSKSCN9A | |
| SCHEMBL27203733 | 0.90 | PPARA (0.53) | PPARGPPARACTSSCTSKSCN9A | |
| SCHEMBL4390581 | 0.86 | CTSS (0.48) | KLK5PPARGPPARATACR1CTSS | |
| SCHEMBL3856557 | 0.86 | CTSS (0.48) | KLK5PPARGPPARATACR1CTSS | |
| SCHEMBL4390584 | 0.86 | CTSS (0.48) | KLK5PPARGPPARATACR1CTSS | |
| SCHEMBL30825582 | 0.86 | TACR1 (0.49) | KLK5TACR1CTSSCTSKSCN9A | |
| SCHEMBL27213605 | 0.85 | TACR1 (0.49) | KLK5PPARGPPARATACR1CTSS | |
| SCHEMBL30825606 | 0.84 | KLK5 (0.47) | KLK5PPARGPPARATACR1CTSS | |
| SCHEMBL30825573 | 0.83 | CTSS (0.43) | KLK5PPARGPPARATACR1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132524-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS, LLC | 2024-04-25 | — | — | US | disclosed |
| WO-2024064210-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS, LLC (US) | 2024-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132524-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | NME2, BTD, BLVRB | KLK5 2119/4885PPARG 2965/4885PPARA 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.